Two-Drug Weight-Loss Approach Shows Promise; GLP-1 Drug Plus Muscle-Builder Outperforms Alone
In a phase II trial of about 500 adults with obesity, adding the muscle-preserving antibody bimagrumab to the GLP-1 drug semaglutide produced greater weight and fat loss and less lean-mass loss than semaglutide alone over 48 weeks (with Week 72 data showing continued fat-loss advantage and lean-mass preservation). Safety was in line with known profiles. If confirmed, this combo could represent a new obesity treatment avenue, though traditional strategies like resistance training and adequate protein intake remain important for preserving muscle during weight loss.
